GLP-1 receptor agonists – China In-Depth – GLP-1 Receptor Agonists – China In-Depth – China
China’s GLP-1 receptor agonist market is set for robust expansion, driven by the rising prevalence of type 2 diabetes (T2D), obesity, and comorbidities such as chronic kidney disease (CKD) and heart failure. Current market leaders include Novo Nordisk’s Ozempic and Wegovy, alongside Eli Lilly’s Mounjaro, which benefits from strong clinical confidence and growing adoption. The June 2025 approval of Innovent’s Xinermei (mazdutide), a dual GCGR / GLP-1 RA, represents a pivotal milestone, underscoring China’s strategic shift toward domestically developed metabolic therapies. Looking ahead, the late-phase pipeline—including orforglipron, survodutide, CagriSema, HRS-7535, VCT-220, noiiglutide, and HRS9531—is expected to intensify competition and expand multi-indication coverage. Over the next decade, pricing strategies, NRDL negotiations, and volume-based procurement (VBP) will be critical in determining access and uptake across different indications.
QUESTIONS ANSWERED
- What are the key growth drivers and constraints influencing China’s GLP-1 therapy market, and how will the market outlook change through 2034?
- What are interviewed experts’ insights into current GLP-1 therapies?
- How will late-phase pipeline entrants influence the competitive landscape and overall market outlook?
- What are the critical market access considerations—including NRDL and VBP—and how will they affect uptake and affordability of GLP-1 therapies across different indications?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events
Release Date
December 2025
Geographies
China
Data source
Draws on forecast data for GLP-1 RA therapies from four Clarivate China In-Depth studies—Type 2 Diabetes, Obesity / Overweight, Chronic Kidney Disease, and Heart Failure—supported by qualitative and quantitative insights from five expert interviews and surveys with 50 thought leaders for each indication in China
Drug treatments
Coverage of key current and late-phase emerging therapies
